Improving Metabolism With HDL Cholesterol

This study is currently recruiting participants.

Verified by Bayside Health, October 2006

First Received: October 31, 2006 No Changes Posted

Sponsors and Collaborators:	Bayside Health Baker Heart Research Institute
Information provided by:	Bayside Health
ClinicalTrials.gov Identifier:	NCT00395148

Purpose

High levels of good cholesterol (HDL) in our blood decreases our chance of having a heart attack. This relates in part to the role good cholesterol plays in reducing build up of fat in the arteries. However, good cholesterol has many other protective effects. We have recently identified three enzymes (proteins) activated by HDL in cells lining the blood vessels, which may be responsible for some of HDL’s protective actions.

Condition	Intervention
Heart Disease	Drug: rHDL

MedlinePlus related topics: Cholesterol Heart Diseases

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment
Official Title:	A Novel Mechanism Mediating Anti-Atherosclerotic and Metabolic Actions of HDL Cholesterol

Further study details as provided by Bayside Health:

Primary Outcome Measures:

Metabolic parameters

Estimated Enrollment:	20
Study Start Date:	March 2006

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Aged 18 – 65 years
Free of overt coronary disease
Body mass index <35 kg.m-2
Fasting plasma glucose > 7 mmol/L-1
No major illness

Exclusion Criteria:

Unable to give informed consent
Smokers
Abnormal LFT, U&E, FBE or creatinine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00395148

Contacts

Contact: Bronwyn A Kingwell, PhD

+613 9276 3261

b.kingwell@alfred.org.au

Locations

Australia, Victoria
Alfred Hospital	Recruiting
Melbourne, Victoria, Australia, 3004

Sponsors and Collaborators

Bayside Health

Baker Heart Research Institute

Investigators

Principal Investigator:

Bronwyn A Kingwell, PhD

Baker Heart Research Institute

More Information

No publications provided by Bayside Health

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Drew BG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, de Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation. 2009 Apr 21;119(15):2103-11. Epub 2009 Apr 6.

Study ID Numbers:	175/04
Study First Received:	October 31, 2006
Last Updated:	October 31, 2006
ClinicalTrials.gov Identifier:	NCT00395148 History of Changes
Health Authority:	Australia: Therapeutic Goods Administration

Study placed in the following topic categories:

Heart Diseases

Additional relevant MeSH terms:

Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 07, 2009